Search
Vertex Pharmaceuticals Inc
VRTXAdd to Watchlist
510.720USD
+2.380+0.47%
Close 09-21 16:00（ET）
129.38BMarket Cap
30.04P/E TTM
Vertex Pharmaceuticals Inc (VRTX) Stock Price Target & Forecast
Analyst Rating
Based on 31 analysts giving stock ratings to Vertex Pharmaceuticals Inc in the past month.
Buy
9 Strong Buy
16 Buy
5 Hold
0 Sell
1 Strong Sell
Target Price
569.663USD+12.06%
VRTX Analyst Recommendation Trends
In the current month, VRTX has received 16 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. VRTX average Analyst price target in the last month is 569.663.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
9
9
11
11
11
11
10
9
16
15
17
17
16
17
16
16
5
5
5
5
5
5
6
7
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
31
30
34
34
33
34
33
33
VRTX Analyst Rating for Peer Comparison
Updated: Sep 21, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Pfizer Inc
PFE
5
6
19
1
1
32
Regeneron Pharmaceuticals Inc
REGN
6
15
11
0
0
32
Merck & Co Inc
MRK
8
14
10
0
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
2
0
31
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, VRTX EPS is projected to reach 4.766 in FY2026Q3, following reported EPS of 4.335 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
5.07
4.31
4.74
4.77
4.72
Actual
4.70
4.06
4.34
--
--
Surprise
-7.42%
-5.90%
-8.49%
--
--
FAQs
What is Vertex Pharmaceuticals Inc's expected revenue for the next quarter?
Vertex Pharmaceuticals Inc's expected revenue is 3.41B.
What is Vertex Pharmaceuticals Inc's price target?
Analysts forecast that Vertex Pharmaceuticals Inc's price target is USD 569.66, with the highest forecast at USD 672.00 and the lowest forecast at USD 350.00.
How have Vertex Pharmaceuticals IncVRTX's recent earnings per share performed?
The market expectation was USD 4.34, while Vertex Pharmaceuticals IncVRTX's earnings per share (EPS) for the previous quarter was USD 4.06. EPS for the next quarter is expected at USD 4.77.
What is the analyst rating for Vertex Pharmaceuticals Inc?
Based on the ratings of Vertex Pharmaceuticals Inc's stock from 31 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.